Poxviral promoters for improving the immunogenicity of MVA delivered vaccines

Human Vaccines & Immunotherapeutics
Naif Khalaf Alharbi

Abstract

Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV/AIDS, influenza, and tuberculosis, MERS-CoV, and Ebola virus infection. There is accumulating data from many preclinical and clinical studies that highlights the excellent safety and immunogenicity of MVA. However, due to the complex nature of many pathogens and their pathogenicity, MVA vectored vaccine candidates need to be optimised to improve their immunogenicity. One of the main approaches to improve MVA immunogenicity focuses on optimising poxviral promoters that drive recombinant vaccine antigens, encoded within recombinant MVA vector genome. A number of promoters were described or optimised to improve the development of MVA based vaccines such as p7.5, pF11, and mH5 promoters. This review focuses on poxviral promoters, their optimisation, genetic stability, and clinical use.

References

Dec 1, 1990·Journal of Virology·P HirschmannH G Stunnenberg
Dec 20, 1989·Journal of Molecular Biology·A J Davison, B Moss
Dec 20, 1989·Journal of Molecular Biology·A J Davison, B Moss
Jun 1, 1988·Journal of Virology·J F Schmitt, H G Stunnenberg
Oct 1, 1986·The Journal of General Virology·M Mackett, G L Smith
Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D Panicali, E Paoletti
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·V BronteN P Restifo
Jun 1, 1997·Journal of Virological Methods·J M HammondB E Coupar
Aug 15, 2003·The Journal of General Virology·Steven S Broyles
Oct 8, 2003·Current Drug Targets. Infectious Disorders·Gerd Sutter, Caroline Staib
Nov 16, 2004·Journal of Virological Methods·Xu LiuSteven S Broyles
Dec 30, 2004·The Journal of Experimental Medicine·David C TscharkeJonathan W Yewdell
Sep 15, 2005·Vaccine·Alexandra TimmPaul Chaplin
Sep 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Carla OseroffAlessandro Sette
Apr 21, 2007·Science in China. Series C, Life Sciences·LiShu ZhangWenZheng Jiang
Feb 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Erika AssarssonAlessandro Sette
Sep 5, 2008·Expert Review of Vaccines·Bruce Acres, Jean-Yves Bonnefoy
Jan 12, 2010·Human Vaccines·Adrian V S HillSimon J Draper
Jun 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Zhilong YangBernard Moss

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.